KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Current Deferred Revenue (2019 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Current Deferred Revenue for 5 consecutive years, with $42.8 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Current Deferred Revenue fell 69.25% year-over-year to $42.8 million, compared with a TTM value of $42.8 million through Sep 2023, down 69.25%, and an annual FY2022 reading of $222.6 million, up 17.65% over the prior year.
  • Current Deferred Revenue was $42.8 million for Q3 2023 at Ginkgo Bioworks Holdings, down from $222.6 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $222.6 million in Q4 2022 and bottomed at $200000.0 in Q4 2019.
  • Average Current Deferred Revenue over 5 years is $92.6 million, with a median of $42.8 million recorded in 2023.
  • The sharpest move saw Current Deferred Revenue soared 14311.5% in 2020, then plummeted 69.25% in 2023.
  • Year by year, Current Deferred Revenue stood at $200000.0 in 2019, then skyrocketed by 14311.5% to $28.8 million in 2020, then skyrocketed by 556.42% to $189.2 million in 2021, then increased by 17.65% to $222.6 million in 2022, then plummeted by 80.79% to $42.8 million in 2023.
  • Business Quant data shows Current Deferred Revenue for DNA at $42.8 million in Q3 2023, $222.6 million in Q4 2022, and $139.0 million in Q3 2022.